The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

Zhu DT, Park A, Lai A. et al. Multiple myeloma incidence and mortality trends in the United States, 1999–2020. Sci Rep. 2024; 14:14564.

Myeloma articles from across Nature Portfolio Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 ...